Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- XL Sci Tech Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- H1Z8MEH658H9
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (Provided by Applicant): The feasibility of continuous and
economical microfabrication of timed-bioresorbable glass microspheres
containing yttrium-90 (Y-90) at therapeutic concentrations has been
successfully demonstrated using Y-89 surrogate in the Phase I research. The
microspheres are uniform in size and chemistry, and the timed-bioresorption
characteristics can be predetermined according to the isotope half-life and the
dosimetry requirements. A dependable commercial supply of Y-90 glass
microspheres will have a positive impact on localized radiation therapy
worldwide. This Phase II research has the objective of making such a supply a
commercial reality. The proposed microfabrication process can be streamlined
and fully automated from Y-90 isotope extraction to packaged Y-90 microspheres
ready for delivery and treatment injection. The microsphere production process
will be optimized with regard to minimized personnel radiation exposure,
maximized use of source radioisotopes, much shortened overall process time to
preserve radioactivity, and above all, much reduced cost. Microspheres
containing therapeutic concentrations of radioisotopes will be evaluated in
vitro for radioactivity retention, biocompatibility, and completeness of
bioresorption; and in vivo to demonstrate the efficacy of the Y-90 microspheres
in treating tumor-bearing rodents.
PROPOSED COMMERCIAL APPLICATIONS:
Timed-bioresorbable glass microspheres containing Y-90 are ideal for direct intratumoral injection in the treatment of cancers such as the liver, pancreas, or the synovectomy of rheumatoid arthritis. Microspheres containing other radioactive isotopes such as P-32 can also be readily produced by the methods described.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
17 SBIR/STTR records share this UEI (1995–2021). Reported award amounts total $7,991,308. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards